Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

genera d.d., svetonedeljska cesta 2, kalinovica, 10436 rakov potok, hrvatska - oksitetraciklin; neomicin; sulfadimidin; sulfagvanidin; citratna kiselina - premiks za izradu ljekovite hrane za životinje - antibakterijski vmp za sustavne infekcije - svinja (prasadi), kokoši (pilića), kunića, činčila

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bomi-lab d.o.o., zagreb - in vitro dijagnostika, probirni testovi na 20 i 88 nutritivne alergene

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

baxter d.o.o., letališka cesta 29a, ljubljana, slovenija - maslinovo ulje, rafinirano i sojino ulje, rafinirano alanin arginin aspartatna kiselina glutamatna kiselina glicin histidin izoleucin leucin lizinacetat metionin fenilalanin prolin serin treonin triptofan tirozin valin glukoza hidrat - emulzija za infuziju - 40 g/l+56,9 g/l+110 g/l - urbroj: 1 plastična vrećica sastoji se od odjeljka s 400 ml 27,5%-tne otopine glukoze, odjeljka s 400 ml 14,2%-tne otopine aminokiselina i odjeljka s 200 ml 20%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 1000 ml

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

baxter d.o.o., letališka cesta 29a, ljubljana, slovenija - maslinovo ulje, rafinirano i sojino ulje, rafinirano alanin arginin aspartatna kiselina glutamatna kiselina glicin histidin izoleucin leucin lizinacetat metionin fenilalanin prolin serin treonin triptofan tirozin valin natrijev acetat trihidrat natrijev glicerofosfat, hidratizirani kalijev klorid magnezijev klorid heksahidrat kalcijev klorid dihidrat glukoza hidrat - emulzija za infuziju - 40 g/l+44,3 g/l+140 g/l - urbroj: 1 plastična vrećica sastoji se od odjeljka s 800 ml 35%-tne otopine glukoze, odjeljka s 800 ml 11,1 %-tne otopine aminokiselina i odjeljka s 400 ml 20%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 2000 ml

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

baxter d.o.o., letališka cesta 29a, ljubljana, slovenija - maslinovo ulje, rafinirano i sojino ulje, rafinirano alanin arginin aspartatna kiselina glutamatna kiselina glicin histidin izoleucin leucin lizinacetat metionin fenilalanin prolin serin treonin triptofan tirozin valin natrijev acetat trihidrat natrijev glicerofosfat, hidratizirani kalijev klorid magnezijev klorid heksahidrat kalcijev klorid dihidrat glukoza hidrat - emulzija za infuziju - 40 g/l+56,9 g/l+110 g/l - urbroj: 1 plastična vrećica sastoji se od odjeljka s 400 ml 27,5%-tne otopine glukoze, odjeljka s 400 ml 14,2%-tne otopine aminokiselina i odjeljka s 200 ml 20%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 1000 ml; 1 plastična vrećica sastoji se od odjeljka s 800 ml 27,5%-tne otopine glukoze, odjeljka s 800 ml 14,2%-tne otopine aminokiselina i odjeljka s 400 ml 20%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 2000 ml

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

baxter d.o.o., letališka cesta 29a, ljubljana, slovenija - maslinovo ulje, rafinirano i sojino ulje, rafinirano alanin arginin aspartatna kiselina glutamatna kiselina glicin histidin izoleucin leucin lizinacetat metionin fenilalanin prolin serin treonin triptofan tirozin valin natrijev acetat trihidrat natrijev glicerofosfat kalijev klorid magnezijev klorid heksahidrat kalcijev klorid dihidrat glukoza hidrat - emulzija za infuziju - 30 g/l+25,3 g/l+75 g/l - urbroj: 1 plastična vrećica sastoji se od odjeljka s 400 ml 18,75%-tne otopine glukoze, odjeljka s 400 ml 6,3%-tne otopine aminokiselina i odjeljka s 200 ml 15%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 1000 ml 1 plastična vrećica sastoji se od odjeljka s 800 ml 18,75%-tne otopine glukoze, odjeljka s 800 ml 6,3%-tne otopine aminokiselina i odjeljka s 400 ml 15%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 2000 ml

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

baxter d.o.o., letališka cesta 29a, ljubljana, slovenija - maslinovo ulje, rafinirano sojino ulje, rafinirano alanin arginin aspartatna kiselina glutamatna kiselina glicin histidin izoleucin leucin lizinacetat metionin fenilalanin prolin serin treonin triptofan tirozin valin natrijev acetat trihidrat natrijev glicerofosfat, hidratizirani kalijev klorid magnezijev klorid heksahidrat kalcijev klorid dihidrat glukoza hidrat - emulzija za infuziju - 35,0 g/l + 75,9 g/l + 73,3 g/l - urbroj: 1 plastična vrećica sastoji se od odjeljka sa 173 ml 27,5%-tne otopine glukoze, odjeljka s 347 ml 14,2%-tne otopine aminokiselina i odjeljka sa 130 ml 17,5%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 650 ml; 1 plastična vrećica sastoji se od odjeljka s 267 ml 27,5%-tne otopine glukoze, odjeljka s 533 ml 14,2%-tne otopine aminokiselina i odjeljka s 200 ml 17,5%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 1000 ml; 1 plastična vrećica sastoji se od odjeljka sa 400 ml 27,5%-tne otopine glukoze, odjeljka s 800 ml 14,2%-tne otopine aminokiselina i odjeljka sa 300 ml 17,5%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 1500 ml; 1 plastična vrećica sastoji se od odjeljka s 533 ml 27,5%-tne otopine glukoze, odjeljka s 1067 ml 14,2%-tne otopine aminokiselina i odjeljka sa 400 ml 17,5%-tne emulzije lipida; ukupni volumen pripremljene mješavine je 2000 ml;

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.

Europska Unija - hrvatski - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - imunosupresivi - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. tretman teških, aktivnog i uznapredovalog reumatoidnog artritisa kod odraslih, ne ranije liječenih metotreksat. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita smanjuje brzinu progresije oštećenja zglobova kao što se mjeri x-ray i poboljšava fizičke funkcije, imenovanje u kombinaciji s metotreksatom. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita može biti dano kao monoterapija u slučaju netolerancije метотрексата ili pri stalnom liječenju s metotreksat je nepraktično (na učinkovitost u monoterapija vidi odjeljak 5. Адалимумаб ne ima dugu povijest u bolesnika u dobi od manje od 2 godine. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita smanjuje brzinu progresije periferne lezije zgloba, mjereno pomoću x-zraka u bolesnika s полиартикулярным mogućnost simetrične podtipovi bolesti (vidi odjeljak 5. 1) i poboljšava fizičke značajke. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 i 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Europska Unija - hrvatski - EMA (European Medicines Agency)

samsung bioepis nl b.v. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; hidradenitis suppurativa; arthritis - imunosupresivi - reumatoidni arthritisimraldi u kombinaciji s metotreksatom prikazana za:liječenje umjereni do teški, aktivan reumatoidni artritis kod odraslih pacijenata, kada odgovor na bolest-модифицирующих противоревматических lijekova, uključujući i metotreksat, bio je neadekvatno. tretman teških, aktivnog i uznapredovalog reumatoidnog artritisa kod odraslih, ne ranije liječenih metotreksat. imraldi može biti dano kao monoterapija u slučaju netolerancije метотрексата ili pri stalnom liječenju s metotreksat je nepraktično. Адалимумаб, kao što je prikazano, kako bi se smanjila brzina progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisimraldi in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. Адалимумаб ne ima dugu povijest u bolesnika u dobi od manje od 2 godine. enthesitis-related arthritisimraldi is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asimraldi is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psorijatični arthritisimraldi indiciran za liječenje aktivnog i uznapredovalog psorijatični artritis kod odraslih, kad odgovor na prethodni заболевани-дорабатывая anti-reumatskih napitke terapija je bila neadekvatna.. adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5. 1) i poboljšati tjelesne funkcije. psoriasisimraldi indiciran za liječenje umjerene do teške kronične plak psorijaze kod odraslih pacijenata koji su kandidati za sistemske terapije. vrtić plak psoriasisimraldi indiciran za liječenje teških oblika kroničnog бляшечного psorijaze u djece i adolescenata od 4-ih godina, koji su imali neadekvatan odgovor ili neprikladne kandidate za lokalne liječenje i phototherapies. hidradenitis suppurativa (hs)imraldi is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 i 5. kruna diseaseimraldi indiciran za liječenje reumatoidnog crohnove bolesti, kod odraslih pacijenata koji se nisu odazvali, unatoč potpuni i odgovarajući tečaj terapija sa kortikosteroidima i/ili imunosupresivima, ili koji ne podnose ili imaju medicinske kontraindikacije za takvu terapiju. paediatric crohn's diseaseimraldi is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or haveulcerative colitisimraldi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisimraldi is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisimraldi is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whomcorticosteroid treatment is inappropriate. paediatric uveitisimraldi is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.